期刊文献+

孕激素受体状态对雌激素受体阳性乳腺癌的病理特征、复发特点及预后的影响 被引量:4

下载PDF
导出
摘要 目的分析孕激素受体(PR)状态与雌激素受体(ER)阳性乳腺癌预后的关系。方法收集ER阳性晚期乳腺癌患者183例,根据PR状态的不同将患者分成(PR+组和PR-组),分析这些患者的复发转移特征、治疗效果及预后。结果 183例ER阳性晚期乳腺癌患者中,PR+组患者105例,PR-组患者78例,两组患者中位发病年龄分别为43岁和49岁,未绝经患者PR+组为65.7%,PR-组为48.7%,绝经患者两组分别为34.3%和51.3%,Ki-67高表达(≥30%)患者两组分别为31.4%和57.7%,人类表皮生长因子受体(HER)-2阳性率两组分别为15.2%和35.9%,脉管癌栓发生率两组分别是21.9%和50.0%,组织学分级(Ⅲ级)分别为11.4%和32.1%,内脏转移发生率分别为36.1%和51.2%,骨转移发生率分别为43.8%和44.9%,7年无病生存期(DFS)分别为47.3%和31.8%。结论与PR+患者相比,PR-患者高表达Ki-67、HER-2更容易发生内脏转移,DFS较短,预后差。
出处 《中国老年学杂志》 CSCD 北大核心 2015年第10期2734-2736,共3页 Chinese Journal of Gerontology
  • 相关文献

参考文献9

  • 1Chad J. Creighton,C. Kent Osborne,Marc J. Vijver,John A. Foekens,Jan G. Klijn,Hugo M. Horlings,Dimitry Nuyten,Yixin Wang,Yi Zhang,Gary C. Chamness,Susan G. Hilsenbeck,Adrian V. Lee,Rachel Schiff.Molecular profiles of progesterone receptor loss in human breast tumors[J]. Breast Cancer Research and Treatment . 2009 (2)
  • 2Taucher Susanne,Rudas Margaretha,Mader Robert M,Gnant Michael,Dubsky Peter,Bachleitner Thomas,Roka Sebastian,Fitzal Florian,Kandioler Daniela,Sporn Emanuel,Friedl Josef,Mittlb?ck Martina,Jakesz Raimund.Do we need HER-2/neu testing for all patients with primary breast carcinoma?. Cancer . 2003
  • 3Grazia Arpino,Heidi Weiss,Adrian V. Lee,Rachel Schiff,Sabino De Placido,C. Kent Osborne,Richard M. Elled.Estrogen Receptor?Positive, Progesterone Receptor?Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance. Journal of the National Cancer Institute . 2005
  • 4Horwitz K B,Alexander P S.In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. The Journal of Endocrinology . 1983
  • 5Xiaojiang Cui,Rachel Schiff,Grazia Arpino,C. Kent Osborne,Adrian V. L.Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy. Japanese Journal of Clinical Oncology . 2005
  • 6Huang H J,Neven P,Drijkoningen M,Paridaens R,Wildiers H,Van Limbergen E,Berteloot P,Amant F,Vergote I,Christiaens M R.Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. Journal of clinical pathology . 2005
  • 7Valerie-Jeanne Bardou,Grazia Arpino,Richard M. Elledge,C. Kent Osborne,Gary M. Cla.Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases. Japanese Journal of Clinical Oncology . 2003
  • 8C. Kent Osborne,Jiang Shou,Suleiman Massarweh,Rachel Schi.Crosstalk between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in Breast Cancer. Clinical Cancer Research . 2005
  • 9Rakha Emad A,El-Sayed Maysa E,Green Andrew R,Paish E Claire,Powe Desmond G,Gee Julia,Nicholson Robert I,Lee Andrew H S,Robertson John F R,Ellis Ian O.Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . 2007

同被引文献22

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部